About IgGenix
IgGenix is a Healthcare company based in San Francisco (United States) founded in 2019 by Stephen Quake and Kari Nadeau. Therapeutic solutions for food allergies are developed via antibody platforms. IgGenix has raised $75 million across 3 funding rounds from investors including Lilly, ARE and Khosla Ventures. IgGenix offers products and services including IGNX001 and SEQ SIFTER. Its focus areas include Life Sciences, Toxicology, Drugs and Genomics. Its legal entity is IgGenix, Inc. Its competitors include BridgeBio, Spark Therapeutics and Alnylam; 3 of its 3 listed competitors have raised funding.
Company details
IgGenix was founded in 2019 and is based in San Francisco, United States. Operations focus on the biotechnology sector, where antibody-based therapeutic platforms are developed to address food allergies. Single-cell genomic technology is utilized to analyze rare human B cells that bind allergens. Immune-modulating activities from the IgG antibody class are incorporated to suppress allergic reactions and monitor conditions.
- Headquarters San Francisco, United States
- Founders Stephen Quake, Kari Nadeau
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website iggenix.com
- Social LinkedIn X
- Legal Name Iggenix, Inc.
- Total Equity Funding$75M (USD)
in 3 rounds
- Latest Funding Round$40M (USD), Series B
Feb 2023
- InvestorsLilly
& 6 more
Products & Services of IgGenix
IgGenix offers a comprehensive portfolio of products and services, including IGNX001 and SEQ SIFTER.
Injectable treatment that blocks allergic reactions for peanut allergy
RNA-sequencing tool for identifying rare antibodies in human blood samples
Funding Insights of IgGenix
IgGenix has successfully raised a total of $75M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $40 million completed in February 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $75M
- Total Rounds 3
- Last Round Series B — $40M
- First Round $10M
(Aug 2020)
- Investors Count 7
All 3 funding rounds of IgGenix with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2023 | $40M | Series B | – | Alexandria | |
| Jul 2021 | $25M | Series A | – | Khosla Ventures, Matthias Westman | |
| Aug 2020 | $10M | Series A | – | Khosla Ventures | – |
7 investors in total: 5 institutional and 2 angel.
Investors in IgGenix
IgGenix has secured backing from 7 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Lilly, ARE and Khosla Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage startups are funded by this venture capital firm. | 2004 | khoslaventures.com | Menlo Park, United States | |
Venture capital investments are focused on food allergy solutions. | 2020 | allerfund.com | ||
| shangbaycapital.com | ||||
REIT that invests in campuses, multi-tenant spaces and build-to-suit facilities in the US | 1994 | are.com | Pasadena, United States | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | lilly.com | United States | |
SP Sean Parker | American entrepreneur, angel investor, known for Napster and Facebook, active in India. | unknown_fdb5d271dc074bbcb | ||
MW Matthias Westman | unknown_acafa9ad950547ce8 |
Investor details for IgGenix
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of IgGenix
15 people are tracked at IgGenix (5 in leadership, 6 in board & advisors, 4 in team).
| Name | Role | Group |
|---|---|---|
Stephen Quake | Co-Founder | Leadership |
Kari Nadeau | Co-Founder | Leadership |
Henry Lowman | Interim Chief Scientific Officer | Leadership |
Derek Croote | CTO | Leadership |
Jessica Grossman | CEO | Leadership |
Samir Kaul | Director | Board & advisors |
Hans Oettgen | Scientific Advisor | Board & advisors |
Jim Wells | Scientific Advisor | Board & advisors |
Scott Smith | Scientific Advisor | Board & advisors |
Mattias Westman | Director | Board & advisors |
Joel S. Marcus | Director | Board & advisors |
Joyce Wong | Antibody Engineering Scientist | Team |
Laurence Nore | EVP, Business Development & Operations | Team |
Paige Creeks | Research Associate III | Team |
Johanna Romero | Research Associate | Team |
Complete people profiles for IgGenix
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of IgGenix
3 dated milestones of IgGenix across 4 years, from founding to its latest funding, stage changes and deals.
- Founded IgGenix is founded.
- Funding First funding round of $10.0M.
- Funding Latest funding round, Series B, of $40.0M.
Competitors of IgGenix
IgGenix has 3 listed competitors in our database, 3 of them funded. They include BridgeBio, Spark Therapeutics and Alnylam.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. |
Detailed competitors of IgGenix
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of IgGenix
The website of IgGenix (iggenix.com) receives about 1.7K visits a month.
- Monthly visits1.7K
▲ 12.6% vs previous month
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as IgGenix (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Iggenix
Complete news archive for IgGenix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about IgGenix
IgGenix was founded in 2019 and raised its 1st funding round 1 year after it was founded.
IgGenix is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
IgGenix is a funded company, having raised a total of $75M across 3 funding rounds to date. The company's 1st funding round was a Series A of $10M, raised on Aug 2020.
IgGenix was founded in 2019 and is based in San Francisco, United States. Operations focus on the biotechnology sector, where antibody-based therapeutic platforms are developed to address food allergies. Single-cell genomic technology is utilized to analyze rare human B cells that bind allergens. Immune-modulating activities from the IgG antibody class are incorporated to suppress allergic reactions and monitor conditions.
IgGenix's top competitors include Spark Therapeutics, BridgeBio and Alnylam.
IgGenix offers IGNX001 and SEQ SIFTER.
IgGenix has 7 investors. Key investors include Lilly, ARE, Khosla Ventures, AllerFund, and Sean Parker.
IgGenix operates through Iggenix, Inc..